The company expired its plan on September 11, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.505 USD | -0.33% |
|
-5.94% | -20.79% |
06-06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
06-05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.79% | 122M | |
+59.32% | 846B | |
+38.56% | 628B | |
-4.33% | 360B | |
+17.29% | 322B | |
+9.36% | 297B | |
+14.15% | 240B | |
+3.11% | 224B | |
+16.98% | 223B | |
+13.28% | 173B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-Mab 's Equity Buyback announced on August 23, 2022 has expired with repurchase of 1,960,638 shares, representing 2.36% for $6.8 million.